Beta Bionics (NASDAQ:BBNX) Coverage Initiated at Bank of America

Bank of America began coverage on shares of Beta Bionics (NASDAQ:BBNX) in a note issued to investors on Monday, Marketbeat reports. The firm set a “buy” rating on the stock.

Several other research firms have also commented on BBNX. Stifel Nicolaus initiated coverage on shares of Beta Bionics in a research report on Monday. They issued a “buy” rating and a $25.00 price target on the stock. LADENBURG THALM/SH SH assumed coverage on Beta Bionics in a report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target for the company. Baird R W raised Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Leerink Partners assumed coverage on Beta Bionics in a research report on Monday. They issued an “outperform” rating and a $28.00 price objective on the stock. Finally, Robert W. Baird started coverage on Beta Bionics in a report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target for the company. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $24.83.

Beta Bionics Trading Down 6.9 %

NASDAQ BBNX opened at $19.17 on Monday. Beta Bionics has a 12-month low of $19.08 and a 12-month high of $24.50.

Insider Buying and Selling at Beta Bionics

In related news, insider Mike Mensinger bought 33,350 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was purchased at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the transaction, the insider now directly owns 59,019 shares of the company’s stock, valued at $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the transaction, the insider now directly owns 3,901,599 shares in the company, valued at $66,327,183. The trade was a 34.46 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.